434 reports of this reaction
1.7% of all AVAPRITINIB reports
#12 most reported adverse reaction
PERIPHERAL SWELLING is the #12 most commonly reported adverse reaction for AVAPRITINIB, manufactured by Blueprint Medicines Corporation. There are 434 FDA adverse event reports linking AVAPRITINIB to PERIPHERAL SWELLING. This represents approximately 1.7% of all 25,335 adverse event reports for this drug.
Patients taking AVAPRITINIB who experience peripheral swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PERIPHERAL SWELLING is a less commonly reported adverse event for AVAPRITINIB, but still significant enough to appear in the safety profile.
In addition to peripheral swelling, the following adverse reactions have been reported for AVAPRITINIB:
The following drugs have also been linked to peripheral swelling in FDA adverse event reports:
PERIPHERAL SWELLING has been reported as an adverse event in 434 FDA reports for AVAPRITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PERIPHERAL SWELLING accounts for approximately 1.7% of all adverse event reports for AVAPRITINIB, making it a notable side effect.
If you experience peripheral swelling while taking AVAPRITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.